LEIDEN, Netherlands, April 11, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHAR.AS) announced today that the Company will present at the UBS Northern Europe Small and Mid Cap Conference (April 12-14, 2005) in London.
Pharming will be represented by Samir Singh, Vice President and Managing Director, US at the conference on April 12, 2005. For further information on the UBS Northern Europe Small and Mid Cap Conference, please visit http://www.ibb.ubs.com/Conferences/co_highlights.
Background on Pharming Group N.V.
Pharming Group N.V. is developing innovative protein therapeutics for unmet medical needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, and intermediates for various applications. Pharming's lead product (recombinant human C1 inhibitor) for hereditary angioedema is in Phase III of clinical development. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.